Abstract
Reversible protein tyrosine phosphorylation, catalysed by the counter-actors protein tyrosine phosphatases (PTPs) and protein tyrosine kinases (PTKs), is a fundamentally important regulatory mechanism of proteins in living cells, controlling cell communication, proliferation, differentiation, motility, and molecular trafficking. The activities of PTPs and PTKs are derailed in several diseases such as cancer and type II diabetes, making them attractive drug targets. Developing drugs against PTKs has started a decade earlier than that on PTPs, and at present there are several molecules targeting PTKs on the market. PTPs in turn are of raising interest, with PTP1B on the lead for its effects on type II diabetes and obesity. In the search for modulators of PTP activity, high-throughput methods are important as the initial step to find suitable lead compounds for drug development. Also, high-throughput methods are very useful in elucidating the specific function of different PTPs. In this review, the different high-throughput studies performed to find inhibitors and activators of classical PTPs are discussed.
Keywords: High throughput screens (HTS), TCPTP, SHP-2, LAR, LYP, CD45, RTK, DiFMUP, pNPP, HTS, OMFP
Anti-Cancer Agents in Medicinal Chemistry
Title: High-Throughput Methods in Identification of Protein Tyrosine Phosphatase Inhibitors and Activators
Volume: 11 Issue: 1
Author(s): Elina Mattila and Johanna Ivaska
Affiliation:
Keywords: High throughput screens (HTS), TCPTP, SHP-2, LAR, LYP, CD45, RTK, DiFMUP, pNPP, HTS, OMFP
Abstract: Reversible protein tyrosine phosphorylation, catalysed by the counter-actors protein tyrosine phosphatases (PTPs) and protein tyrosine kinases (PTKs), is a fundamentally important regulatory mechanism of proteins in living cells, controlling cell communication, proliferation, differentiation, motility, and molecular trafficking. The activities of PTPs and PTKs are derailed in several diseases such as cancer and type II diabetes, making them attractive drug targets. Developing drugs against PTKs has started a decade earlier than that on PTPs, and at present there are several molecules targeting PTKs on the market. PTPs in turn are of raising interest, with PTP1B on the lead for its effects on type II diabetes and obesity. In the search for modulators of PTP activity, high-throughput methods are important as the initial step to find suitable lead compounds for drug development. Also, high-throughput methods are very useful in elucidating the specific function of different PTPs. In this review, the different high-throughput studies performed to find inhibitors and activators of classical PTPs are discussed.
Export Options
About this article
Cite this article as:
Mattila Elina and Ivaska Johanna, High-Throughput Methods in Identification of Protein Tyrosine Phosphatase Inhibitors and Activators, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/187152011794941235
DOI https://dx.doi.org/10.2174/187152011794941235 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Matrix Metalloproteinases as Therapeutic Targets in Cancer
Current Cancer Drug Targets Are Selenoproteins Important for the Cancer Protective Effects of Selenium?
Current Nutrition & Food Science C-KIT Signaling in Cancer Treatment
Current Pharmaceutical Design C. elegans Genetic Networks Predict Roles for O-GlcNAc Cycling in Key Signaling Pathways
Current Signal Transduction Therapy Actual and Potential Agents and Biomarkers in the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis
Current Cancer Drug Targets Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer
Current Computer-Aided Drug Design Regulation of the Urokinase Receptor (uPAR) by LDL Receptor-related Protein-1 (LRP1)
Current Pharmaceutical Design Relevance of the Neuropeptide Y System in the Biology of Cancer Progression
Current Topics in Medicinal Chemistry Cytotoxicity, Docking Study of New Fluorinated Fused Pyrimidine Scaffold: Thermal and Microwave Irradiation Synthesis
Medicinal Chemistry Subject Index To Volume 1
Recent Patents on Anti-Cancer Drug Discovery Targeting of Cancer-Related Proteins with PNA Oligomers
Current Cancer Drug Targets Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Positron Emission Tomography (PET) in the Evaluation of Response to Therapy in Non-Small Cell Lung Cancer
Current Cancer Therapy Reviews Molecular Determinants of Colon Cancer Susceptibility in the East and West
Current Molecular Medicine Cellular and Molecular Mechanisms of Tumor-Induced T-Cell Tolerance
Current Cancer Drug Targets Patenting of Nanopharmaceuticals in Drug Delivery: No Small Issue
Recent Patents on Drug Delivery & Formulation Synthesis and Biological Evaluation of Novel Thiazol-2yl-amine Derivatives as Potential Anticancer Agents
Letters in Organic Chemistry Polyisoprenylated Cysteinyl Amide Inhibitors Deplete K-Ras and Induce Caspase-dependent Apoptosis in Lung Cancer Cells
Current Cancer Drug Targets Interstitial Lung Disease in Sjogrens Syndrome
Current Rheumatology Reviews